Literature DB >> 32112817

Super-enhancers: A new frontier for glioma treatment.

Meng Cheng1, Zheng Wei Zhang1, Xing Hu Ji1, Yadi Xu1, Erbao Bian2, Bing Zhao3.   

Abstract

Glioma is the most common primary malignant tumor in the human brain. Although there are a variety of treatments, such as surgery, radiation and chemotherapy, glioma is still an incurable disease. Super-enhancers (SEs) are implicated in the control of tumor cell identity, and they promote oncogenic transcription, which supports tumor cells. Inhibition of the SE complex, which is required for the assembly and maintenance of SEs, may repress oncogenic transcription and impede tumor growth. In this review, we discuss the unique characteristics of SEs compared to typical enhancers, and we summarize the recent advances in the understanding of their properties and biological role in gene regulation. Additionally, we highlight that SE-driven lncRNAs, miRNAs and genes are involved in the malignant phenotype of glioma. Most importantly, the application of SE inhibitors in different cancer subtypes has introduced new directions in glioma treatment.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glioma; Long non-coding RNAs; Super-enhancers; miRNA

Year:  2020        PMID: 32112817     DOI: 10.1016/j.bbcan.2020.188353

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  10 in total

1.  MYC-mediated upregulation of PNO1 promotes glioma tumorigenesis by activating THBS1/FAK/Akt signaling.

Authors:  Xu Chen; Zheng-Qian Guo; Dan Cao; Yong Chen; Jian Chen
Journal:  Cell Death Dis       Date:  2021-03-04       Impact factor: 8.469

2.  A Signature of Nine lncRNA Methylated Genes Predicts Survival in Patients With Glioma.

Authors:  Meng Cheng; Libo Sun; Kebing Huang; Xiaoyu Yue; Jie Chen; Zhengwei Zhang; Bing Zhao; Erbao Bian
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

3.  Clinicopathological and Prognostic Significance of ABCC3 in Human Glioma.

Authors:  Dan-Dong Fang; Wei Huang; Gang Cheng; Xiao-Nan Liu; Shi-Min Liu; Bao-Sen Hou; Jian Mao; Hu Zhou
Journal:  J Oncol       Date:  2021-12-23       Impact factor: 4.375

4.  Early 2 factor (E2F) transcription factors contribute to malignant progression and have clinical prognostic value in lower-grade glioma.

Authors:  Haitao Luo; Chuming Tao; Xiaoyan Long; Xingen Zhu; Kai Huang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Ligand-modified homologous targeted cancer cell membrane biomimetic nanostructured lipid carriers for glioma therapy.

Authors:  Mengyu Chen; Yuexin Cui; Wenyan Hao; Yueyue Fan; Jingqiu Zhang; Qianqian Liu; Mingrui Jiang; Yang Yang; Yingzi Wang; Chunsheng Gao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 6.  The Emerging Roles of LINC00665 in Human Cancers.

Authors:  Jing Zhu; Yirao Zhang; Xuyu Chen; Yibo Bian; Juan Li; Keming Wang
Journal:  Front Cell Dev Biol       Date:  2022-03-09

7.  8-oxodG accumulation within super-enhancers marks fragile CTCF-mediated chromatin loops.

Authors:  Giovanni Scala; Francesca Gorini; Susanna Ambrosio; Andrea M Chiariello; Mario Nicodemi; Luigi Lania; Barbara Majello; Stefano Amente
Journal:  Nucleic Acids Res       Date:  2022-04-08       Impact factor: 16.971

8.  miR-497-5p-RSPO2 axis inhibits cell growth and metastasis in glioblastoma.

Authors:  Kun Chen; Zheng Wang; Qi-Bei Zong; Meng-Ying Zhou; Qing-Fa Chen
Journal:  J Cancer       Date:  2022-01-24       Impact factor: 4.207

9.  A Novel Defined Pyroptosis-Related Gene Signature for Predicting Prognosis and Treatment of Glioma.

Authors:  Zhihao Yang; Zhigang Chen; Yu Wang; Zhiwei Wang; Deran Zhang; Xiaoyu Yue; Yinfei Zheng; Lianxin Li; Erbao Bian; Bing Zhao
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

10.  Histone demethylase JMJD1C promotes the polarization of M1 macrophages to prevent glioma by upregulating miR-302a.

Authors:  Chuanhong Zhong; Bei Tao; Feilong Yang; Kaiguo Xia; Xiaobo Yang; Ligang Chen; Tangming Peng; Xiangguo Xia; Xianglong Li; Lilei Peng
Journal:  Clin Transl Med       Date:  2021-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.